#MusicSky
#MusicChallenge
Day 10 - First
“First Glimmer” by Paul Westerberg
m.youtube.com/watch?v=PCfS...
#MusicSky
#MusicChallenge
Day 10 - First
“First Glimmer” by Paul Westerberg
m.youtube.com/watch?v=PCfS...
"Compared to placebo, LDN at doses up to 4.5 mg/day for 16 weeks was well tolerated but did not improve fatigue severity in people with PCFS."
#MECFS
"Compared to placebo, LDN at doses up to 4.5 mg/day for 16 weeks was well tolerated but did not improve fatigue severity in people with PCFS."
#MECFS
"Compared to placebo, LDN at doses up to 4.5 mg/day for 16 weeks was well tolerated but did not improve fatigue severity in people with PCFS."
"our results contrast with suggested benefits of LDN in open uncontrolled studies in Long COVID or ME/CFS"
#mecfs #longcovid
"Compared to placebo, LDN at doses up to 4.5 mg/day for 16 weeks was well tolerated but did not improve fatigue severity in people with PCFS."
"our results contrast with suggested benefits of LDN in open uncontrolled studies in Long COVID or ME/CFS"
#mecfs #longcovid
PCFS is a study-specific label for “ME/CFS per IOM with infectious trigger”. The formulation
2/16
PCFS is a study-specific label for “ME/CFS per IOM with infectious trigger”. The formulation
2/16
The study does 𝑛𝑜𝑡 demonstrate a mean benefit of LDN 1 to 4.5 mg with rapid up-titration over 16 weeks in PCFS, subject to the absence of peer review. The study tests neither slow titration (which would have been interesting and more
4/16
The study does 𝑛𝑜𝑡 demonstrate a mean benefit of LDN 1 to 4.5 mg with rapid up-titration over 16 weeks in PCFS, subject to the absence of peer review. The study tests neither slow titration (which would have been interesting and more
4/16
Low Dose Naltrexone for Post-COVID Fatigue Syndrome: A Randomized Controlled Trial
www.medrxiv.org/content/10.6...
A disappointing result
#LongCovid #MEcfs #PwME #CFS
Low Dose Naltrexone for Post-COVID Fatigue Syndrome: A Randomized Controlled Trial
www.medrxiv.org/content/10.6...
A disappointing result
#LongCovid #MEcfs #PwME #CFS
www.medrxiv.org/content/10.6...
www.medrxiv.org/content/10.6...
Patients met the 2015 Institute of Medicine ME/CFS criteria, except that symptoms were required to follow COVID-19 and to have lasted at least 3, rather than 6 months.
Patients met the 2015 Institute of Medicine ME/CFS criteria, except that symptoms were required to follow COVID-19 and to have lasted at least 3, rather than 6 months.
Low-dose naltrexone (LDN) did not significantly improve fatigue, pain, physical activity, or quality of life compared with placebo after 16 weeks.
www.medrxiv.org/content/10.6...
Low-dose naltrexone (LDN) did not significantly improve fatigue, pain, physical activity, or quality of life compared with placebo after 16 weeks.
www.medrxiv.org/content/10.6...
Final cave: this is only a preprint.
www.medrxiv.org/content/10.6...
Final cave: this is only a preprint.
www.medrxiv.org/content/10.6...
dianabirkelbach.wordpress.com/2026/10/20/p...
dianabirkelbach.wordpress.com/2026/10/20/p...